Identity recordInvestigational clinical program
What Pemvidutide resolves to
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
- Evidence lane
- Clinical pipeline profile
- Current record
- Phase 2 programs active; MASH Phase 3 planned
- Checked
- July 18, 2026
ALT-801balanced GLP-1/glucagon dual agonistAltimmune pemvidutide
Destination recordRegulated therapeutic-goods market
What Australia still has to prove
An Australia-specific guide to separating ARTG-listed or registered therapeutic goods, practitioner and pharmacy services, personal imports, and research-only listings before comparing cost.
- Comparison mode
- AUD / ARTG & register checks
- Price coverage
- No Australian table yet
- Guide updated
- July 18, 2026